Nautilus Biotechnology, Inc.·4

Mar 4, 6:37 PM ET

Patel Sujal M 4

4 · Nautilus Biotechnology, Inc. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-04
Patel Sujal M
DirectorCEO, President, and Secretary10% Owner
Transactions
  • Purchase

    Common Stock

    [F1]
    2026-03-04$2.61/sh+25,000$65,23810,366,721 total
Holdings
  • Common Stock

    [F2]
    (indirect: By LLC)
    5,280,476
  • Common Stock

    [F3]
    (indirect: By Trust)
    1,814,035
Footnotes (3)
  • [F1]Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  • [F2]Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.
  • [F3]Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.
Signature
/s/ Matthew Murphy, as Attorney-in-Fact|2026-03-04

Documents

1 file
  • 4
    wk-form4_1772667437.xmlPrimary

    FORM 4